Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

A Study to Evaluate the Safety, Tolerability, Pharmacokinetic a Single Day of Dosing With GSK1614235.

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: GSK2330672
Drug: Placebo
Drug: GSK1614235

First Posted Date: 2012-05-30

Last Posted Date: 2017-07-26

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 56

Registration Number: NCT01607385

Locations: 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States

A Study to Investigate the Safety and Pharmacodynamics of Repeat Intranasal Administration of the TLR7 Agonist GSK2245035 in Subjects With Respiratory Allergies

Phase 2

Completed

Conditions: Asthma and Rhinitis

Interventions: Drug: GSK2245035
Device: Type 1 amber glass bottle
Other: Placebo

First Posted Date: 2012-05-30

Last Posted Date: 2017-01-30

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 18

Registration Number: NCT01607372

Locations: 🇨🇦
GSK Investigational Site, Toronto, Ontario, Canada

WEUKBRE5557: IMI PROTECT(Work Package 2): Antiepileptics & Suicide

Completed

Conditions: Epilepsy

Interventions: Drug: Lamotrigine use

First Posted Date: 2012-05-30

Last Posted Date: 2015-03-27

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1

Registration Number: NCT01607333

A Clinical Study to Evaluate Experimental Children's Toothpastes in an In-Situ Caries Model

Phase 3

Completed

Conditions: Dental Caries

Interventions: Drug: Placebo
Drug: Fluoride

First Posted Date: 2012-05-30

Last Posted Date: 2014-08-11

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 55

Registration Number: NCT01607411

Locations: 🇺🇸
Indiana University School of Dentistry, Indianapolis, Indiana, United States

Compare the Properties and Characteristics of an Investigational Formulation of Lamotrigine With Placebo

Phase 1

Completed

Conditions: Mental Disorders

Interventions: Drug: Cherry lamotrigine ODT
Drug: Cherry Placebo

First Posted Date: 2012-05-28

Last Posted Date: 2017-08-03

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 24

Registration Number: NCT01607086

Locations: 🇬🇧
GSK Investigational Site, Cambridge, Cambridgeshire, United Kingdom

A Study for Evaluation of Immunogenicity and Reactogenicity of Fluarix/Influsplit SSW 2012/2013 in People Aged 18 Years and Above

Phase 3

Completed

Conditions: Influenza

Interventions: Biological: Fluarix/Influsplit SSW 2012-2013

First Posted Date: 2012-05-28

Last Posted Date: 2018-09-07

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 119

Registration Number: NCT01607112

Locations: 🇩🇪
GSK Investigational Site, Dresden, Sachsen, Germany

Type II Diabetes Mellitus in Patients Exposed to Pravastatin and Paroxetine

Completed

Conditions: Depression, Postpartum

Interventions: Drug: Pravastatin alone
Drug: Paroxetine alone
Drug: Pravastatin and paroxetine combined

First Posted Date: 2012-05-21

Last Posted Date: 2014-07-02

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1

Registration Number: NCT01602913

A Study to Test the Possibility of Cross Reaction Induced by the Idursulfase Drug to GSK2788723

Completed

Conditions: Mucopolysaccharidosis II

Interventions: Drug: Idursulfase
Drug: GSK2788723

First Posted Date: 2012-05-21

Last Posted Date: 2017-09-25

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 10

Registration Number: NCT01602601

Locations: 🇯🇵
GSK Investigational Site, Tokyo, Japan

Lamotrigine Phase III Study in Bipolar I Disorder

Phase 3

Completed

Conditions: Bipolar Disorder

Interventions: Drug: Placebo
Drug: Lamotrigine

First Posted Date: 2012-05-21

Last Posted Date: 2017-01-23

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 265

Registration Number: NCT01602510

Locations: 🇨🇳
GSK Investigational Site, Shanghai, China

Valaciclovir Hydrochloride Phase III for Hematopoietic Stem Cell Transplantation Patients

Phase 3

Completed

Conditions: Herpes Simplex

Interventions: Drug: VACV tablets (Adults or pediatrics) or granules (pediatrics)

First Posted Date: 2012-05-21

Last Posted Date: 2018-08-17

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 40

Registration Number: NCT01602562

Locations: 🇯🇵
GSK Investigational Site, Tokyo, Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy